{"gene":"ADRA1A","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2022,"finding":"ADRA1A physically and functionally couples with Gαq to promote adipocyte thermogenesis; this signaling depends on effector proteins of the futile creatine cycle, creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP). Combined Gαq and Gαs signaling selectively in adipocytes promotes whole-body energy expenditure, and CKB is required for this effect.","method":"Genetic loss-of-function (adipocyte-selective knockout), pharmacological manipulation, gene expression analysis, physical coupling assays in adipocytes, in vivo metabolic phenotyping","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional coupling demonstrated, multiple orthogonal methods (KO, pharmacology, gene expression, in vivo phenotyping), replicated across multiple experimental paradigms in single rigorous study","pmids":["36344764"],"is_preprint":false},{"year":2025,"finding":"SNS-driven noradrenaline (NA) release activates Adra1a in acinar and myoepithelial cells of the lacrimal gland to regulate mitochondrial Ucp2 and inhibit tear secretion; pharmacological, surgical, and genetic blockade of Adra1a increases tear secretion and alleviates dry eye signs.","method":"Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, genetic knockout, live imaging, multiple dry eye mouse models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (pharmacological, surgical, genetic) with defined cellular and physiological phenotypes, mechanistic pathway (Adra1a→Ucp2) established","pmids":["40473608"],"is_preprint":false},{"year":2024,"finding":"NE acts directly on cortical astrocytes via Adra1a adrenergic receptors to elicit sustained increases in intracellular calcium; this calcium signal invokes purinergic pathways that signal to neurons via adenosine A1 receptors, mediating post-reinforcement behavioral improvement.","method":"Chemogenetic blockade of astrocytic calcium elevation, receptor-specific pharmacology (A1 receptor blockade), in vivo calcium imaging, behavioral assays, prefrontal cortex neuronal encoding analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (chemogenetics, pharmacology, in vivo imaging) in single preprint study, not yet peer-reviewed","pmids":["bio_10.1101_2024.10.24.620009"],"is_preprint":true},{"year":2023,"finding":"Adra1a-deficient mice in a pregnancy-associated hypertensive (PAH) model exhibit more severe cardiac hypertrophy than PAH mice with intact Adra1a, and Adra1a mRNA levels in the heart are regulated by the renin-angiotensin system (Ang II reduces Adra1a expression).","method":"Adra1a-deficient mouse model, comprehensive cardiac gene expression analysis, comparison of PAH vs. control mice","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined cardiac phenotype, transcriptomic analysis identifying RAS regulation of Adra1a, single lab","pmids":["36736425"],"is_preprint":false},{"year":2021,"finding":"miR-3682 inactivates AMPK signaling by negatively targeting ADRA1A; ADRA1A knockdown partially offsets the inhibitory effect of miR-3682 inhibitor on HCC cell growth and mobility, placing ADRA1A upstream of AMPK in this pathway.","method":"Dual-luciferase reporter assay confirming miR-3682 targeting of ADRA1A 3'UTR, siRNA knockdown, western blot of AMPK pathway proteins, cell viability/migration assays","journal":"Annals of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — target validation by luciferase assay plus functional rescue experiments, single lab with multiple assay types","pmids":["34706275"],"is_preprint":false},{"year":2017,"finding":"ADRA1A is a direct target of miR-19b and miR-16; inhibition of these miRNAs increases ADRA1A expression and reduces caspase 3/7 activation, decreasing cardiomyocyte apoptosis in a DOCA-induced hypertensive heart disease model.","method":"miRNA inhibitor/antagomir treatment, real-time PCR, western blot, caspase 3/7 activity assay, DOCA-induced HHD mouse model","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional miRNA-target relationship demonstrated with multiple assays and in vivo model, but target validation method (luciferase) not explicitly confirmed in abstract","pmids":["28531963"],"is_preprint":false},{"year":2024,"finding":"Leonurine improves hepatic lipid metabolism through the ADRA1a/AMPK/SCD1 axis, reducing hepatic lipid synthesis in NAFLD; molecular docking and molecular biology experiments verified ADRA1a as the target of leonurine action upstream of AMPK.","method":"Transcriptomic analysis, lipidomics, molecular docking, western blot of AMPK pathway proteins, NAFLD mouse model (high-fat high-sugar diet)","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — molecular docking is computational; western blot provides some support but mechanistic placement is inferential from a single lab without reconstitution or direct binding assay","pmids":["39409181"],"is_preprint":false},{"year":2010,"finding":"The human ADRA1A gene generates at least 10 alternative transcripts via four distinct mechanisms: transposable element integration, differential promoter usage, substitution of 3' splice sites during primate evolution, and an unknown mechanism; six transcripts were experimentally validated by RT-PCR and sequencing.","method":"RT-PCR, sequencing, in silico analysis of alternative splicing","journal":"Genes & genetic systems","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct experimental validation of six transcript variants by RT-PCR and sequencing, mechanistic classification of splicing events","pmids":["20410666"],"is_preprint":false},{"year":2025,"finding":"Irisin regulates energy metabolism in hypoxic cardiomyocytes via the ADRA1A-AMPK pathway; protective effects of Irisin on mitochondrial membrane potential and ATP production are diminished by AMPK inhibitor Compound C, placing ADRA1A upstream of AMPK in this context.","method":"HL-1 cardiomyocyte hypoxia model, qPCR, western blot, mitochondrial membrane potential measurement, ATP production assay, Compound C inhibition, CHF mouse model with cardiac ultrasound","journal":"European journal of medical research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement inferred from pharmacological inhibition without direct ADRA1A-specific genetic manipulation; single lab, single study","pmids":["40660392"],"is_preprint":false}],"current_model":"ADRA1A is a Gαq-coupled α1-adrenergic receptor that, upon noradrenaline stimulation, activates downstream effectors including the futile creatine cycle (via CKB and TNAP) to drive adipocyte thermogenesis, suppresses tear secretion in lacrimal gland acinar/myoepithelial cells via mitochondrial Ucp2, and mediates sustained astrocytic calcium elevations that invoke purinergic-neuronal signaling to support learning; it also functions upstream of AMPK in cardiac and hepatic energy metabolism, and its expression is regulated by the renin-angiotensin system and by microRNAs (miR-19b, miR-16, miR-3682) that target its 3'UTR."},"narrative":{"mechanistic_narrative":"ADRA1A is a Gαq-coupled α1-adrenergic receptor that transduces sympathetic noradrenergic input into tissue-specific metabolic and secretory responses [PMID:36344764, PMID:40473608]. In adipocytes it physically and functionally couples to Gαq to drive thermogenesis, an effect that requires effectors of the futile creatine cycle—creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP)—and contributes to whole-body energy expenditure [PMID:36344764]. In lacrimal gland acinar and myoepithelial cells, sympathetically released noradrenaline activates ADRA1A to engage mitochondrial Ucp2 and suppress tear secretion, such that blockade of the receptor increases tearing and relieves dry-eye signs [PMID:40473608]. In cortical astrocytes, noradrenaline acting through ADRA1A elicits sustained intracellular calcium elevations that recruit purinergic signaling to neurons via adenosine A1 receptors [PMID:bio_10.1101_2024.10.24.620009]. Across cardiac and hepatic contexts ADRA1A functions upstream of AMPK signaling, with receptor loss exacerbating cardiac hypertrophy in a pregnancy-associated hypertensive model [PMID:36736425, PMID:34706275]. ADRA1A expression is constrained by the renin-angiotensin system, where angiotensin II lowers cardiac Adra1a mRNA [PMID:36736425], and by microRNAs (miR-19b, miR-16, miR-3682) that target its 3'UTR [PMID:34706275, PMID:28531963]; the human gene additionally produces multiple alternative transcripts through transposable-element integration, differential promoter usage, and evolutionary 3' splice-site substitution [PMID:20410666].","teleology":[{"year":2010,"claim":"Before its signaling roles were dissected, the transcriptional complexity of the human gene was unresolved; characterizing its transcript repertoire established that ADRA1A is diversified by multiple distinct mechanisms.","evidence":"RT-PCR, sequencing, and in silico analysis of alternative splicing of the human gene","pmids":["20410666"],"confidence":"Medium","gaps":["Functional consequences of individual transcript variants not determined","No link between specific isoforms and tissue-specific receptor activities"]},{"year":2017,"claim":"To explain how ADRA1A levels are tuned in cardiac disease, miRNA regulation was tested, showing the receptor is post-transcriptionally repressed by miR-19b and miR-16 with downstream consequences for cardiomyocyte survival.","evidence":"miRNA inhibitor/antagomir treatment with qPCR, western blot, and caspase 3/7 assays in a DOCA-induced hypertensive heart disease mouse model","pmids":["28531963"],"confidence":"Medium","gaps":["Direct 3'UTR binding by luciferase not explicitly confirmed","Mechanism linking ADRA1A level to apoptosis not defined"]},{"year":2021,"claim":"The pathway position of ADRA1A in liver cancer signaling was unknown; placing it upstream of AMPK connected receptor expression to a metabolic-kinase axis controlling tumor cell growth.","evidence":"Dual-luciferase 3'UTR reporter, siRNA knockdown, AMPK pathway western blots, and viability/migration assays in HCC cells (miR-3682)","pmids":["34706275"],"confidence":"Medium","gaps":["Mechanism by which receptor signaling modulates AMPK not resolved","In vivo relevance not tested"]},{"year":2022,"claim":"How ADRA1A drives energy expenditure was undefined; demonstrating Gαq coupling and dependence on the futile creatine cycle established a concrete effector mechanism for adipocyte thermogenesis.","evidence":"Adipocyte-selective knockout, pharmacology, physical coupling assays, and in vivo metabolic phenotyping in mice","pmids":["36344764"],"confidence":"High","gaps":["Structural basis of Gαq coupling not resolved","Relative contributions of CKB versus TNAP not separated"]},{"year":2023,"claim":"The upstream control of cardiac ADRA1A and its protective role were unclear; loss-of-function plus transcriptomics showed the receptor restrains cardiac hypertrophy and is downregulated by the renin-angiotensin system.","evidence":"Adra1a-deficient mouse pregnancy-associated hypertension model with cardiac gene expression analysis","pmids":["36736425"],"confidence":"Medium","gaps":["Direct mechanism of Ang II repression of Adra1a not established","Single-lab phenotype"]},{"year":2024,"claim":"Whether ADRA1A signaling acts in non-neuronal CNS cells was untested; showing noradrenaline-evoked astrocytic calcium signaling that propagates to neurons via adenosine A1 receptors placed the receptor in a glial-neuronal circuit supporting learning.","evidence":"Chemogenetic blockade, receptor-specific pharmacology, in vivo calcium imaging, and behavioral assays (preprint)","pmids":["bio_10.1101_2024.10.24.620009"],"confidence":"Medium","gaps":["Not peer-reviewed","Direct receptor-to-calcium coupling in astrocytes not isolated genetically","Identity of purinergic mediators not fully defined"]},{"year":2024,"claim":"Extending the ADRA1A/AMPK axis to hepatic lipid metabolism, leonurine was reported to act through an ADRA1a/AMPK/SCD1 pathway to reduce NAFLD lipid synthesis.","evidence":"Transcriptomics, lipidomics, molecular docking, and AMPK pathway western blots in an NAFLD mouse model","pmids":["39409181"],"confidence":"Low","gaps":["Receptor placement inferred from computational docking without direct binding or genetic ablation","No reconstitution of the axis"]},{"year":2025,"claim":"ADRA1A's role in tear physiology was unknown; multi-modal blockade established that sympathetic noradrenaline drives lacrimal ADRA1A to engage Ucp2 and suppress tear secretion, identifying it as a dry-eye target.","evidence":"Pharmacological, surgical sympathectomy, and genetic knockout approaches with live imaging across multiple dry-eye mouse models","pmids":["40473608"],"confidence":"High","gaps":["Coupling between ADRA1A and Ucp2 regulation not mechanistically resolved","Cell-type-specific contributions of acinar versus myoepithelial cells not separated"]},{"year":2025,"claim":"Irisin's cardioprotective signaling was linked to ADRA1A by showing its mitochondrial and ATP effects in hypoxic cardiomyocytes depend on AMPK downstream of the receptor.","evidence":"HL-1 hypoxia model with Compound C AMPK inhibition, mitochondrial membrane potential and ATP assays, and a CHF mouse model","pmids":["40660392"],"confidence":"Low","gaps":["Pathway placement inferred from pharmacological inhibition without ADRA1A-specific genetic manipulation","Direct Irisin–ADRA1A interaction not shown"]},{"year":null,"claim":"How a single Gαq-coupled receptor selects among divergent tissue-specific outputs—creatine-cycle thermogenesis, Ucp2-dependent secretory suppression, astrocytic calcium signaling, and AMPK regulation—remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying mechanism links receptor coupling to divergent effectors","Structural/conformational determinants of effector selection unknown","Contribution of distinct transcript isoforms to tissue-specific signaling untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,6]}],"complexes":[],"partners":["GNAQ","CKB","TNAP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25100","full_name":"Alpha-1D adrenergic receptor","aliases":["Alpha-1A adrenergic receptor","Alpha-1D adrenoreceptor","Alpha-1D adrenoceptor","Alpha-adrenergic receptor 1a"],"length_aa":572,"mass_kda":60.5,"function":"Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C (PubMed:7746284). ADRA1D binds the catecholamine ligands norepinephrine and epinephrine (PubMed:7815325, PubMed:8024574, PubMed:8183249)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P25100/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADRA1A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADRA1A","total_profiled":1310},"omim":[{"mim_id":"604406","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-13; GNA13","url":"https://www.omim.org/entry/604406"},{"mim_id":"604394","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-12; GNA12","url":"https://www.omim.org/entry/604394"},{"mim_id":"190196","title":"TRANSGLUTAMINASE 2; TGM2","url":"https://www.omim.org/entry/190196"},{"mim_id":"104221","title":"ALPHA-1A-ADRENERGIC RECEPTOR; ADRA1A","url":"https://www.omim.org/entry/104221"},{"mim_id":"104219","title":"ALPHA-1D-ADRENERGIC RECEPTOR; ADRA1D","url":"https://www.omim.org/entry/104219"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":20.5},{"tissue":"liver","ntpm":56.2}],"url":"https://www.proteinatlas.org/search/ADRA1A"},"hgnc":{"alias_symbol":["ADRA1L1"],"prev_symbol":["ADRA1C"]},"alphafold":{"accession":"P25100","domains":[{"cath_id":"1.20.1070.10","chopping":"91-297_333-425","consensus_level":"medium","plddt":86.0404,"start":91,"end":425}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25100","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25100-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25100-F1-predicted_aligned_error_v6.png","plddt_mean":64.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADRA1A","jax_strain_url":"https://www.jax.org/strain/search?query=ADRA1A"},"sequence":{"accession":"P25100","fasta_url":"https://rest.uniprot.org/uniprotkb/P25100.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25100/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25100"}},"corpus_meta":[{"pmid":"36344764","id":"PMC_36344764","title":"ADRA1A-Gαq signalling potentiates adipocyte thermogenesis through CKB and TNAP.","date":"2022","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36344764","citation_count":52,"is_preprint":false},{"pmid":"19352218","id":"PMC_19352218","title":"Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A.","date":"2009","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19352218","citation_count":30,"is_preprint":false},{"pmid":"31933413","id":"PMC_31933413","title":"Promoter aberrant methylation status of ADRA1A is associated with hepatocellular carcinoma.","date":"2020","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31933413","citation_count":25,"is_preprint":false},{"pmid":"28531963","id":"PMC_28531963","title":"MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28531963","citation_count":22,"is_preprint":false},{"pmid":"19918262","id":"PMC_19918262","title":"ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19918262","citation_count":21,"is_preprint":false},{"pmid":"22037178","id":"PMC_22037178","title":"Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22037178","citation_count":19,"is_preprint":false},{"pmid":"15136785","id":"PMC_15136785","title":"A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.","date":"2004","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/15136785","citation_count":17,"is_preprint":false},{"pmid":"21519279","id":"PMC_21519279","title":"Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population.","date":"2011","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21519279","citation_count":16,"is_preprint":false},{"pmid":"34706275","id":"PMC_34706275","title":"MiR-3682 promotes the progression of hepatocellular carcinoma (HCC) via inactivating AMPK signaling by targeting ADRA1A.","date":"2021","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34706275","citation_count":13,"is_preprint":false},{"pmid":"39409181","id":"PMC_39409181","title":"Leonurine Inhibits Hepatic Lipid Synthesis to Ameliorate NAFLD via the ADRA1a/AMPK/SCD1 Axis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39409181","citation_count":10,"is_preprint":false},{"pmid":"40473608","id":"PMC_40473608","title":"A gatekeeper sympathetic control of lacrimal tear secretion and dry eye onset through the NA-Adra1a-Ucp2 pathway.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40473608","citation_count":7,"is_preprint":false},{"pmid":"17408692","id":"PMC_17408692","title":"No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population.","date":"2007","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/17408692","citation_count":6,"is_preprint":false},{"pmid":"36736425","id":"PMC_36736425","title":"Increased angiotensin II coupled with decreased Adra1a expression enhances cardiac hypertrophy in pregnancy-associated hypertensive mice.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36736425","citation_count":4,"is_preprint":false},{"pmid":"27379509","id":"PMC_27379509","title":"The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.","date":"2016","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27379509","citation_count":4,"is_preprint":false},{"pmid":"35964682","id":"PMC_35964682","title":"Hypermethylation in the promoter region of the ADRA1A gene is associated with opioid use disorder in Han Chinese.","date":"2022","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/35964682","citation_count":3,"is_preprint":false},{"pmid":"20410666","id":"PMC_20410666","title":"Four different ways of alternative transcripts generation mechanism in ADRA1A gene.","date":"2010","source":"Genes & genetic systems","url":"https://pubmed.ncbi.nlm.nih.gov/20410666","citation_count":3,"is_preprint":false},{"pmid":"37820700","id":"PMC_37820700","title":"Hsa_circ_0080608 Attenuates Lung Cancer Progression by Functioning as a Competitive Endogenous RNA to Regulate the miR-661/ADRA1A Pathway.","date":"2023","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/37820700","citation_count":2,"is_preprint":false},{"pmid":"19102884","id":"PMC_19102884","title":"[Association between ADRA1A gene polymorphism and autoantibodies against the alpha1-adrenergic receptor in hypertensive patients.].","date":"2008","source":"Zhonghua xin xue guan bing za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/19102884","citation_count":2,"is_preprint":false},{"pmid":"36012699","id":"PMC_36012699","title":"Vascular Reactions of the Diving Reflex in Men and Women Carrying Different ADRA1A Genotypes.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012699","citation_count":2,"is_preprint":false},{"pmid":"40660392","id":"PMC_40660392","title":"Irisin regulates cardiac myocyte energy metabolic remodeling involved the ADRA1A-AMPK signaling pathwayng pathway.","date":"2025","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/40660392","citation_count":1,"is_preprint":false},{"pmid":"41473249","id":"PMC_41473249","title":"Prostogrit mitigates testosterone/estradiol induced prostatic enlargement/remodeling in rat model of benign prostatic hyperplasia and fine-tunes prostatic expression of Adra1a and Il6 genes.","date":"2025","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41473249","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.24.620009","title":"Cortical norepinephrine-astrocyte signaling critically mediates learned behavior","date":"2024-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.24.620009","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13441,"output_tokens":2303,"usd":0.037434,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9487,"output_tokens":3254,"usd":0.064393,"stage2_stop_reason":"end_turn"},"total_usd":0.101827,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"ADRA1A physically and functionally couples with Gαq to promote adipocyte thermogenesis; this signaling depends on effector proteins of the futile creatine cycle, creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP). Combined Gαq and Gαs signaling selectively in adipocytes promotes whole-body energy expenditure, and CKB is required for this effect.\",\n      \"method\": \"Genetic loss-of-function (adipocyte-selective knockout), pharmacological manipulation, gene expression analysis, physical coupling assays in adipocytes, in vivo metabolic phenotyping\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional coupling demonstrated, multiple orthogonal methods (KO, pharmacology, gene expression, in vivo phenotyping), replicated across multiple experimental paradigms in single rigorous study\",\n      \"pmids\": [\"36344764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SNS-driven noradrenaline (NA) release activates Adra1a in acinar and myoepithelial cells of the lacrimal gland to regulate mitochondrial Ucp2 and inhibit tear secretion; pharmacological, surgical, and genetic blockade of Adra1a increases tear secretion and alleviates dry eye signs.\",\n      \"method\": \"Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, genetic knockout, live imaging, multiple dry eye mouse models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (pharmacological, surgical, genetic) with defined cellular and physiological phenotypes, mechanistic pathway (Adra1a→Ucp2) established\",\n      \"pmids\": [\"40473608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NE acts directly on cortical astrocytes via Adra1a adrenergic receptors to elicit sustained increases in intracellular calcium; this calcium signal invokes purinergic pathways that signal to neurons via adenosine A1 receptors, mediating post-reinforcement behavioral improvement.\",\n      \"method\": \"Chemogenetic blockade of astrocytic calcium elevation, receptor-specific pharmacology (A1 receptor blockade), in vivo calcium imaging, behavioral assays, prefrontal cortex neuronal encoding analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (chemogenetics, pharmacology, in vivo imaging) in single preprint study, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.10.24.620009\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Adra1a-deficient mice in a pregnancy-associated hypertensive (PAH) model exhibit more severe cardiac hypertrophy than PAH mice with intact Adra1a, and Adra1a mRNA levels in the heart are regulated by the renin-angiotensin system (Ang II reduces Adra1a expression).\",\n      \"method\": \"Adra1a-deficient mouse model, comprehensive cardiac gene expression analysis, comparison of PAH vs. control mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined cardiac phenotype, transcriptomic analysis identifying RAS regulation of Adra1a, single lab\",\n      \"pmids\": [\"36736425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-3682 inactivates AMPK signaling by negatively targeting ADRA1A; ADRA1A knockdown partially offsets the inhibitory effect of miR-3682 inhibitor on HCC cell growth and mobility, placing ADRA1A upstream of AMPK in this pathway.\",\n      \"method\": \"Dual-luciferase reporter assay confirming miR-3682 targeting of ADRA1A 3'UTR, siRNA knockdown, western blot of AMPK pathway proteins, cell viability/migration assays\",\n      \"journal\": \"Annals of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — target validation by luciferase assay plus functional rescue experiments, single lab with multiple assay types\",\n      \"pmids\": [\"34706275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADRA1A is a direct target of miR-19b and miR-16; inhibition of these miRNAs increases ADRA1A expression and reduces caspase 3/7 activation, decreasing cardiomyocyte apoptosis in a DOCA-induced hypertensive heart disease model.\",\n      \"method\": \"miRNA inhibitor/antagomir treatment, real-time PCR, western blot, caspase 3/7 activity assay, DOCA-induced HHD mouse model\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional miRNA-target relationship demonstrated with multiple assays and in vivo model, but target validation method (luciferase) not explicitly confirmed in abstract\",\n      \"pmids\": [\"28531963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Leonurine improves hepatic lipid metabolism through the ADRA1a/AMPK/SCD1 axis, reducing hepatic lipid synthesis in NAFLD; molecular docking and molecular biology experiments verified ADRA1a as the target of leonurine action upstream of AMPK.\",\n      \"method\": \"Transcriptomic analysis, lipidomics, molecular docking, western blot of AMPK pathway proteins, NAFLD mouse model (high-fat high-sugar diet)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — molecular docking is computational; western blot provides some support but mechanistic placement is inferential from a single lab without reconstitution or direct binding assay\",\n      \"pmids\": [\"39409181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The human ADRA1A gene generates at least 10 alternative transcripts via four distinct mechanisms: transposable element integration, differential promoter usage, substitution of 3' splice sites during primate evolution, and an unknown mechanism; six transcripts were experimentally validated by RT-PCR and sequencing.\",\n      \"method\": \"RT-PCR, sequencing, in silico analysis of alternative splicing\",\n      \"journal\": \"Genes & genetic systems\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct experimental validation of six transcript variants by RT-PCR and sequencing, mechanistic classification of splicing events\",\n      \"pmids\": [\"20410666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Irisin regulates energy metabolism in hypoxic cardiomyocytes via the ADRA1A-AMPK pathway; protective effects of Irisin on mitochondrial membrane potential and ATP production are diminished by AMPK inhibitor Compound C, placing ADRA1A upstream of AMPK in this context.\",\n      \"method\": \"HL-1 cardiomyocyte hypoxia model, qPCR, western blot, mitochondrial membrane potential measurement, ATP production assay, Compound C inhibition, CHF mouse model with cardiac ultrasound\",\n      \"journal\": \"European journal of medical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement inferred from pharmacological inhibition without direct ADRA1A-specific genetic manipulation; single lab, single study\",\n      \"pmids\": [\"40660392\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADRA1A is a Gαq-coupled α1-adrenergic receptor that, upon noradrenaline stimulation, activates downstream effectors including the futile creatine cycle (via CKB and TNAP) to drive adipocyte thermogenesis, suppresses tear secretion in lacrimal gland acinar/myoepithelial cells via mitochondrial Ucp2, and mediates sustained astrocytic calcium elevations that invoke purinergic-neuronal signaling to support learning; it also functions upstream of AMPK in cardiac and hepatic energy metabolism, and its expression is regulated by the renin-angiotensin system and by microRNAs (miR-19b, miR-16, miR-3682) that target its 3'UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADRA1A is a Gαq-coupled α1-adrenergic receptor that transduces sympathetic noradrenergic input into tissue-specific metabolic and secretory responses [#0, #1]. In adipocytes it physically and functionally couples to Gαq to drive thermogenesis, an effect that requires effectors of the futile creatine cycle—creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP)—and contributes to whole-body energy expenditure [#0]. In lacrimal gland acinar and myoepithelial cells, sympathetically released noradrenaline activates ADRA1A to engage mitochondrial Ucp2 and suppress tear secretion, such that blockade of the receptor increases tearing and relieves dry-eye signs [#1]. In cortical astrocytes, noradrenaline acting through ADRA1A elicits sustained intracellular calcium elevations that recruit purinergic signaling to neurons via adenosine A1 receptors [#2]. Across cardiac and hepatic contexts ADRA1A functions upstream of AMPK signaling, with receptor loss exacerbating cardiac hypertrophy in a pregnancy-associated hypertensive model [#3, #4]. ADRA1A expression is constrained by the renin-angiotensin system, where angiotensin II lowers cardiac Adra1a mRNA [#3], and by microRNAs (miR-19b, miR-16, miR-3682) that target its 3'UTR [#4, #5]; the human gene additionally produces multiple alternative transcripts through transposable-element integration, differential promoter usage, and evolutionary 3' splice-site substitution [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Before its signaling roles were dissected, the transcriptional complexity of the human gene was unresolved; characterizing its transcript repertoire established that ADRA1A is diversified by multiple distinct mechanisms.\",\n      \"evidence\": \"RT-PCR, sequencing, and in silico analysis of alternative splicing of the human gene\",\n      \"pmids\": [\"20410666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of individual transcript variants not determined\", \"No link between specific isoforms and tissue-specific receptor activities\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"To explain how ADRA1A levels are tuned in cardiac disease, miRNA regulation was tested, showing the receptor is post-transcriptionally repressed by miR-19b and miR-16 with downstream consequences for cardiomyocyte survival.\",\n      \"evidence\": \"miRNA inhibitor/antagomir treatment with qPCR, western blot, and caspase 3/7 assays in a DOCA-induced hypertensive heart disease mouse model\",\n      \"pmids\": [\"28531963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct 3'UTR binding by luciferase not explicitly confirmed\", \"Mechanism linking ADRA1A level to apoptosis not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The pathway position of ADRA1A in liver cancer signaling was unknown; placing it upstream of AMPK connected receptor expression to a metabolic-kinase axis controlling tumor cell growth.\",\n      \"evidence\": \"Dual-luciferase 3'UTR reporter, siRNA knockdown, AMPK pathway western blots, and viability/migration assays in HCC cells (miR-3682)\",\n      \"pmids\": [\"34706275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which receptor signaling modulates AMPK not resolved\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"How ADRA1A drives energy expenditure was undefined; demonstrating Gαq coupling and dependence on the futile creatine cycle established a concrete effector mechanism for adipocyte thermogenesis.\",\n      \"evidence\": \"Adipocyte-selective knockout, pharmacology, physical coupling assays, and in vivo metabolic phenotyping in mice\",\n      \"pmids\": [\"36344764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Gαq coupling not resolved\", \"Relative contributions of CKB versus TNAP not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The upstream control of cardiac ADRA1A and its protective role were unclear; loss-of-function plus transcriptomics showed the receptor restrains cardiac hypertrophy and is downregulated by the renin-angiotensin system.\",\n      \"evidence\": \"Adra1a-deficient mouse pregnancy-associated hypertension model with cardiac gene expression analysis\",\n      \"pmids\": [\"36736425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism of Ang II repression of Adra1a not established\", \"Single-lab phenotype\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Whether ADRA1A signaling acts in non-neuronal CNS cells was untested; showing noradrenaline-evoked astrocytic calcium signaling that propagates to neurons via adenosine A1 receptors placed the receptor in a glial-neuronal circuit supporting learning.\",\n      \"evidence\": \"Chemogenetic blockade, receptor-specific pharmacology, in vivo calcium imaging, and behavioral assays (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.10.24.620009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not peer-reviewed\", \"Direct receptor-to-calcium coupling in astrocytes not isolated genetically\", \"Identity of purinergic mediators not fully defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extending the ADRA1A/AMPK axis to hepatic lipid metabolism, leonurine was reported to act through an ADRA1a/AMPK/SCD1 pathway to reduce NAFLD lipid synthesis.\",\n      \"evidence\": \"Transcriptomics, lipidomics, molecular docking, and AMPK pathway western blots in an NAFLD mouse model\",\n      \"pmids\": [\"39409181\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Receptor placement inferred from computational docking without direct binding or genetic ablation\", \"No reconstitution of the axis\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"ADRA1A's role in tear physiology was unknown; multi-modal blockade established that sympathetic noradrenaline drives lacrimal ADRA1A to engage Ucp2 and suppress tear secretion, identifying it as a dry-eye target.\",\n      \"evidence\": \"Pharmacological, surgical sympathectomy, and genetic knockout approaches with live imaging across multiple dry-eye mouse models\",\n      \"pmids\": [\"40473608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coupling between ADRA1A and Ucp2 regulation not mechanistically resolved\", \"Cell-type-specific contributions of acinar versus myoepithelial cells not separated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Irisin's cardioprotective signaling was linked to ADRA1A by showing its mitochondrial and ATP effects in hypoxic cardiomyocytes depend on AMPK downstream of the receptor.\",\n      \"evidence\": \"HL-1 hypoxia model with Compound C AMPK inhibition, mitochondrial membrane potential and ATP assays, and a CHF mouse model\",\n      \"pmids\": [\"40660392\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pathway placement inferred from pharmacological inhibition without ADRA1A-specific genetic manipulation\", \"Direct Irisin–ADRA1A interaction not shown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single Gαq-coupled receptor selects among divergent tissue-specific outputs—creatine-cycle thermogenesis, Ucp2-dependent secretory suppression, astrocytic calcium signaling, and AMPK regulation—remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying mechanism links receptor coupling to divergent effectors\", \"Structural/conformational determinants of effector selection unknown\", \"Contribution of distinct transcript isoforms to tissue-specific signaling untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GNAQ\", \"CKB\", \"TNAP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}